<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2800">
  <stage>Registered</stage>
  <submitdate>2/06/2010</submitdate>
  <approvaldate>2/06/2010</approvaldate>
  <nctid>NCT01137019</nctid>
  <trial_identification>
    <studytitle>Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition</studytitle>
    <scientifictitle>Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents</scientifictitle>
    <utrn />
    <trialacronym>OPTIMA</trialacronym>
    <secondaryid>OPTIMA A19/10</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Heart Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Biolimus-eluting stent
Treatment: devices - Everolimus-eluting coronary stent

Active Comparator: Biolimus-eluting stent - 

Active Comparator: Everolimus-eluting stent - 


Treatment: devices: Biolimus-eluting stent
The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.

Treatment: devices: Everolimus-eluting coronary stent
The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of stent strut malapposition - Apposition will be examined immediately following stent implantation following angiographic optimization of stent deployment</outcome>
      <timepoint>0 Days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rate of stent strut tissue coverage - Subjects will be randomized to follow-up at either one of the time points post stenting (3, 6, 12 or 15 months).</outcome>
      <timepoint>At follow-up (one of either 3, 6, 12 or 15 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events</outcome>
      <timepoint>15 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age = 18 years

          -  Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
             infarction

          -  Presence of one or more coronary artery stenosis &gt; 50% in a native coronary artery
             with a reference diameter ranging from 2.25 to 4.0 mm which can be covered with one or
             multiple stents

          -  No limitation to the number of treated lesions, number of vessels or lesion length
             according to the randomization group</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known intolerance to aspirin, clopidogrel, heparin, stainless steel, cobalt chromium,
             Biolimus, everolimus, contrast material

          -  Acute ST-segment elevation myocardial infarction

          -  Bypass graft

          -  Inability to provide informed consent

          -  Pregnancy

          -  Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained
             throughout the peri-surgical period

          -  Left ventricular ejection fraction &lt; 25%

          -  Serum creatinine &gt; 180mmol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Northern Hospital - Epping</hospital>
    <postcode>3076 - Epping</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Dr Peter Barlis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Biosensors International</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to use a high-resolution intracoronary imaging modality, called
      optical coherence tomography (OCT) to examine two different types of coronary artery stents
      used to treat patients with coronary artery disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01137019</trialwebsite>
    <publication>Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, JÃ¼ni P, di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010 Jan;31(2):165-76. doi: 10.1093/eurheartj/ehp480. Epub 2009 Nov 4.
Barlis P, van Soest G, Serruys PW, Regar E. Intracoronary optical coherence tomography and the evaluation of stents. Expert Rev Med Devices. 2009 Mar;6(2):157-67. doi: 10.1586/17434440.6.2.157. Review.
Barlis P, Dimopoulos K, Tanigawa J, Dzielicka E, Ferrante G, Del Furia F, Di Mario C. Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. Int J Cardiol. 2010 May 28;141(2):151-6. doi: 10.1016/j.ijcard.2008.11.204. Epub 2009 Jan 19.
Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol. 2009 May 15;134(2):180-8. doi: 10.1016/j.ijcard.2008.05.069. Epub 2008 Sep 4.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Barlis, MBBS PhD FRACP</name>
      <address>Northern Hospital, Department of Cardiology, Victoria, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>